Universitetet i Oslo, Det Matematisk Naturvitenskapelige Fakultet


Erik Olai Pettersen

Position:

Professor

Address work:


Department of Physics, The University of Oslo, PO Box 1048, Blindern,

N-0316 Oslo, Norway

Fysisk Institutt, Universitetet i Oslo,
Postboks 1048, Blindern 0316, Oslo

Office in rom no:

KV 336, Chemistry Building West

Tel:

Office: 22855644, Lab: 22855651

 

 

Fax

22855671

 

 

E-mail:

Erik Olai Pettersen

Home address:

Tokerudberget 10, 0986 Oslo

Tel home/mobile:

+47 90930743

 

 

 Course:

 Fall 2008: FYS 4720 (Radiobiology)

Education:

1) Civil engineer at the Department for Physics, University of Trondheim, NTH, in 1972. The main subject was biophysics and the thesis was within radiation biophysics studying effects of X-rays on human cells in culture.

2) Dr. philos at the University of Oslo 1979. The title of the doctoral thesis: "Radiosensitization conferred by oxygen and hypoxic cell sensitizers on human cells cultivated in vitro".

Supervision of students in research:

38 students with completed thesis at the master level

10 students with completed doctoral thesis (Dr. philos and Dr. Scient)

Participation in International research networks:

December 1997- Dec 2002: Nordic Academy for Advanced Studies (NorFa): The Nordic Normoxia research Training Network. Co-ordinated by Professor Peter Ebbesen, Laboratory for Stem Cell Research, The Danish Cancer Society.

January 2001-January 2004: EU-Network of Excellence with 16 partners: Proposal no QLRT-1999-30579, Contract No QLRI-2000-00579: Acronym: OXNORM. Project title: Optimizing the Oxygen tension for in vitro cell work. Co-ordinated by Professor Peter Ebbesen, Laboratory for Stem Cell Research, The Danish Cancer Society.

February 2004- February 2007: Nordic Industrial Fund: Project number 02055: titled Transferring Oxygen Biology to Companies. Co-ordinated by Professor Peter Ebbesen, The University of Aalborg, Denmark.

February 2004-February 2009: EU-Integrated Project/large-scale project with 17 Partners (FP6): Proposal/Contract No 502932: Acronym EUROXY. Project title: Targeting newly discovered oxygen-sensing cascades for novel cancer treatments. Biology, equipment, drug candidates. Co-ordinated by Professor Peter Ebbesen, The University of Aalborg, Denmark.

EUROXY contains a program for teaching courses at the PhD level and for training of PhD-students by visiting laboratories of consortium partners. This activity is co-ordinated by Erik Pettersen at the University of Oslo.

Coordinator of international research networks

February 2009-February 2014: EU-Collaborative Project/large-scale project with 22 partners (FP7): Acronym: METOXIA. Project title: Metastatic tumours facilitated by hypoxic tumour micro-environments. The kick-off Meeting was held in Oslo 18th-20th february 2009.

Descendants of a radiation-inactivated cervix cancer cell.

Journal Articles:

  1. Pettersen, E.O., Oftebro, R. & Brustad, T.: X-ray inactivation of human cells in tissue culture under aerobic and hypoxic conditions in the presence and absence of TMPN. Int. J. Radiat. Biol. 24 (1973) 285-296.
  2. Pettersen, E.O., Bøyum, A. & Laane, B.F.M.: X-ray inactivation of murine bone marrow cells as measured by the spleen colony assay and the diffusion chamber technique. Radiat. Res. 58 (1974) 409-416.
  3. Pettersen, E.O., Oftebro, R. & Brustad, T.: Influence of certain technical parameters on the shape of dose-response curves in studies of X-ray inactivation of human cells cultivated in vitro. Int. J. Radiat. Biol. 25 (1974) 99-103.
  4. Pettersen, E.O., Oftebro R. & Brustad, T.: The radiosensitizing and radioprotective effect of the organic nitroxyl-free radical TMPN on extremely hypoxic human cells of line NHIK 3025, cultivated in vitro. Int. J. Radiat. Biol. 26 (1974) 523-534.
  5. Pettersen, E.O., Oftebro, R. & Brustad, T.: Survival after X-irradiation of extremely hypoxic human cells cultured in vitro. Int. J. Radiat. Biol. 26 (1974) 305-310 .
  6. Nerbø-Dahl, W., Oftebro, R., Pettersen, E.O. & Brustad, T.: Inhibitory and cytotoxic effects of oncovin (vincristine sulphate) on cells of human line NHIK 3025. Cancer Res. 36 (1976) 3101-3105.
  7. Bakke, O. & Pettersen, E.O.: A fast and accurate method for calculating Engelberg's synchronization index. Cell Tissue Kinet. 9 (1976) 389-393.
  8. Pettersen, E.O., Oftebro, R. & Brustad, T.: Radiation sensitizing effect of diamide on human cells cultivated in vitro. Acta Radiol. Ther. Phys. Biol. 15 (1976) 551-559.
  9. Pettersen, E.O., Christensen, T., Bakke, O. & Oftebro, R.: A change in the oxygen effect throughout the cell-cycle of human cells of the line NHIK 3025 cultivated in vitro. Int.. J. Radiat. Biol. 31 (1977) 171-184.
  10. Løvhaug, D., Wibe, E., Oftebro, R., Pettersen, E.O. & Brustad, T.: Recovery from X-ray induced damage in human cells grown in culture. Neoplasma 24 (1977) 513-520.
  11. Pettersen, E.O., Bakke, O., Lindmo, T. & Oftebro, R.: Cell cycle characteristics of synchronized and asynchronous populations of human cells and effect of cooling of selected mitotic cells. Cell Tissue Kinet. 10 (1977) 511-522.
  12. Pettersen, E.O. & Lindmo, T.: Effects of different growth conditions on survival after irradiation in hypoxia of human cells (NHIK 3025) in vitro. Acta Radiol. Oncol. 17 (1978) 319-330.
  13. Wibe, E., Oftebro, R., Christensen, T., Laland, S.G., Pettersen, E.O. & Lindmo, T.: Inhibitory effects of the new mitotic inhibitor 5-chloropyrimidin-2-one and of vincristine on human cells in vitro. Cancer Res. 38 (1978) 560-565.
  14. Pettersen, E.O.: Radiosensitizing and toxic effects of the 2-nitroimidazole Ro-07-0582 in different phases of the cell cycle of extremely hypoxic human cells in vitro. Radiat. Res. 73 (1978) 180-191.
  15. Pettersen, E.O.: Toxic and radiosensitizing effect of the 2-nitroimidazole misonidazole (Ro-07-0582) on murine CFU in vivo. Br. J. Cancer Suppl. III 37 (1978) 107-110.
  16. Lindmo, T. & Pettersen, E.O.: Delay of cell cycle progression after X-irradiation of synchronized populations of human cells (NHIK 3025) in culture. Cell Tissue Kinet. 12 (1979) 43-57.
  17. Moan, J., Pettersen, E.O. & Christensen, T.: The mechanism of photodynamic inactivation of human cells in vitro in the presence of haematoporphyrin. Br. J. Cancer 39 (1979) 398-407.
  18. Wibe, E., Oftebro, R., Laland, S.G., Pettersen, E.O. & Lindmo, T.: Cell-cycle inhibitory effects of the mitotic inhibitor NY 3170 on human cells in vitro. Br. J. Cancer 39 (1979) 391-397.
  19. Rønning, Ø., Pettersen, E.O. & Seglen, PO.: Protein synthesis and protein degradation through the cell cycle of human NHIK 3025 cells in vitro. Exp. Cell Res. 123 (1979) 63-72.
  20. Lindmo, T., Pettersen, E.O. & Wibe, E.: Cell-cycle inhibitory effect of misonidazole on human cells cultivated in vitro under aerobic conditions. Br. J. Cancer 40 (1979) 755-760.
  21. Rofstad, E.K., Pettersen, E.O., Lindmo, T. & Oftebro, R.: Proliferation kinetics of cells of the established line NHIK 1922 grown in vitro and as solid tumors in the athymic mutant nude mouse. Cell Tissue Kinet. 13 (1980) 163-171.
  22. Pettersen, E.O. & Lindmo, T.: Low concentrations of misonidazole counteracts effects of extreme hypoxia on cells in S. Br. J. Cancer 43 (1981) 355-366.
  23. Rønning, Ø.W., Lindmo, T., Pettersen, E.O. & Seglen, P.O.: Effect of serum step-down on protein metabolism and proliferation kinetics of NHIK 3025 cells. J. Cell Physiol. 107 (1981) 47-57.
  24. Moan, J. & Pettersen, E.O.: X-irradiation of human cells in culture in the presence of haematoporphyrin. Int. J. Radiat. Biol. 40 (1981) 107-109.
  25. Pettersen, E.O., Olsen, K.J., Jacobsen, A.B. & Andersen, A.: Radiosensitivity of lymphocytes separated from rat lymph nodes and human peripheral blood. Br. J. Radiol. 54 (1981) 923-924.
  26. Pettersen, E.O., Rofstad, E.K. & Brustad, T.: Sensitizing effect of misonidazole on NHIK 1922 cells irradiated in vitro or as solid tumour in athymic nude mice. Acta Radiol. Onc. 20 (1981) 101-108.
  27. Christensen, T., Feren, K., Moan, J. & Pettersen, E.O.: Photodynamic effect of haematoporphyrin derivative on synchronized and asynchronous cells of different origin. Br. J. Cancer 44 (1981) 717-724.
  28. Rønning, Ø.W., Lindmo, T., Pettersen, E.O. & Seglen, P.O.: The role of protein accumulation in the cell cycle control of human NHIK 3025 cells. J. Cell. Physiol. 109 (1981) 411-418.
  29. Pettersen, E.O., Nome, O., Rønning, Ø.W. & Oftebro, R.: Effects of benzaldehyde on survival and cell-cycle kinetics of human cells cultivated in vitro. Eur. J. Cancer Clin. Oncol. 19 (1983) 507-514.
  30. Pettersen, E.O., Rønning, Ø.W., Nome, O. & Oftebro, R.: Effects of benzaldehyde on protein metabolism of human cells cultivated in vitro. Eur. J. Cancer Clin. Onc. 19 (1983) 935-940.
  31. McGhie, J.B., Wold, E., Pettersen, E.O. & Moan, J.: Combined electron radiation and hyperthermia. Repair of DNA strand breaks in NHIK 3025 cells irradiated and incubated at 37, 42.5 and 45oC. Radiat. Res. 96 (1983) 31-40.
  32. Pettersen, E.O. & Lindmo, T.: Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia. Modifications induced by low concentrations of misonidazole present during hypoxia. Br. J. Cancer 48 (1983) 809-817.
  33. Dornish, J., Pettersen, E.O. & Oftebro, R.: Interaction of 1-propargyl-5-chloro-pyrimidin-2-one (a metahalone) with rat brain tubulin. Biochem. Biophys. Acta 797 (1984) 156-162.
  34. Dornish, J.M., Pettersen, E.O., Oftebro, R. & Melvik, J.E.: Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by benzaldehyde. Eur. J. Cancer Clin. Onc. 20 (1984) 1287-1298.
  35. Schwarze, P.E., Pettersen, E.O., Shoaib, M.C. & Seglen, P.O.: Emergence of a population of small, diploid hepatocytes during hepatocarcinogenesis. Carcinogenesis 5 (1984) 1267-1275.
  36. Fosså, S.D., Thorud, E., Shoaib, M.C., Pettersen, E.O., Høie, J. & Scott Knudsen, P: DNA flow cytometry in primary breast carcinoma. Acta Path. Microbiol. Immunol. Scand. 92 (1984) 475-480.
  37. Rønning, .W. & Pettersen, E.O.: Doubling of cell mass is not necessary in order to achieve cell division in cultured human cells. Exp. Cell Res. 155 (1984) 267-272.
  38. Rønning, Ø.W. & Pettersen, E.O.: Effect of different growth factors on cell cycle traverse and protein growth of human cells in culture. Exp. Cell Res. 157 (1985) 29-40.
  39. Pettersen, E.O., Dornish, J.M. & Rønning, Ø.W.: 4,6-benzylidene-D-glucose, a benzaldehyde derivative that inhibits protein synthesis but not mitosis of NHIK 3025 cells. Cancer Res. 45 (1985) 2085-2091.
  40. Pettersen, E.O., Nome, O., Dornish, J.M. & Oftebro, R.: Mitotic arrest and interphase inhibition induced by the pyrimidine sulfoxide NY 4138. Inv. New Drugs 3 (1985) 245-253.
  41. Fosså, S.D., Pettersen, E.O., Thorud, E., Melvik, J.E. & Ous, S.: DNA flow cytometry in human testicular cancer. Cancer Lett. 28 (1985) 55-60.
  42. Tveit, K.M., Pettersen, E.O., Fosså, S.D. & Pihl, A.: Selection of tumour cell subpopulations occurs during cultivation of human tumours in soft agar. A DNA flow cytometric study. Br. J. Cancer 52 (1985) 701-705.
  43. Rogne, S., Rønning, Ø.W., Myklebost, O., Seglen, P.O. & Pettersen, E.O.: Cell cycle traverse and protein metabolism in human NHIK 3025 cells: The role of anchorage. J. Cell. Physiol. 125 (1985) 528-532.
  44. Dornish, J.M. & Pettersen, E.O.: Protection from cis-dichlorodiammineplatinum- induced cell inactivation by aldehydes involves cell membrane amino groups. Cancer Lett. 29 (1985) 235-243.
  45. Schwarze, P.E., Pettersen, E.O. & Seglen, P.O.: Characterization of hepatocytes from carcinogen-treated rats by two-parametric flow cytometry. Carcinogenesis 7 (1986) 171-173.
  46. Fosså, S.D., Thorud, E., Shoaib, M.C. & Pettersen, E.O.: DNA flow cytometry of cells obtained from old paraffin-embedded specimens. Beitr. Path. Bd. 181 (1986) 200-205.
  47. Fosså, S.D., Thorud, E., Pettersen, E.O., Shoaib, M.C., Scott-Knudsen, O. & Ous, S.: DNA flow cytometry in human bladder carcinoma. Beitr. Path. Bd. 181 (1986) 291-295.
  48. Dornish, J.M., Melvik, J.E. & Pettersen, E.O.: Reduced cellular uptake of cis-dichlorodiammineplatinum by benzaldehyde. Anticancer Res. 6 (1986) 583-588.
  49. Pettersen, E.O., Schwarze, P.E., Dornish, J.M. & Nesland, J.M.: Antitumour effect of benzylidene-glucose (BG) in rats with chemically induced hepatocellular carcinoma. Anticancer Res. 6 (1986) 147-152.
  50. Melvik, J.E., Pettersen, E.O., Gordon, P.B. & Seglen, P.O.: Increase in cis-dichlorodiammineplatinum(II) cytotoxicity upon reversible electropermeabilization of the plasma membrane in cultured human NHIK 3025 cells. Eur. Cancer Clin. Onc. 22 (1986) 1523-1530.
  51. Pettersen, E.O., Juul, N.O. & Rønning, Ø.W.: Regulation of protein metabolism of human cells during and after acute hypoxia. Cancer Res. 46 (1986) 4346-4351.
  52. Schwarze, P.E., Pettersen, E.O., Tolleshaug, H. & Seglen, P.O.: Isolation of carcinogen-induced, diploid hepatocytes by centrifugal elutriation. Cancer Res. 46 (1986) 4732-4737.
  53. Nesland, J.M., Pettersen, E.O., Fosså, S.D., Høie, J. & Johannessen, J.V.: Nuclear DNA content in breast carcinomas with neuroendocrine differentiation. J. Pathol. 150 (1986) 181-185.
  54. Melvik, J.E. & Pettersen, E.O.: Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by methionine. Inorg. Chem. Acta 37 (1987) 115-118.
  55. Dornish, J.M., Stokke, T. & Pettersen, E.O.: The effect of benzaldehyde on terbium fluorescence enhancement in human NHIK 3025 cells treated with cis- dichlorodiammineplatinum. Inorg. Chem. Acta 137 (1987) 105-107.
  56. Dornish, J.M., Pettersen, E.O. & Oftebro, R.: Synergistic cell inactivation by cis-dichlorodiammine platinum in combination with 1-propargyl-5-chloropyrimidine-2-one. Br. J. Cancer 56 (1987) 273-278.
  57. Nygaard, M.E.H., Pettersen, E.O., Dornish, J.M. & Oftebro, R.: Inactivation of human cells cultivated in vitro by the new mitotic inhibitors NY 4137 and NY 4138. Invest. New Drugs 5 (1987) 259-266.
  58. Dornish, J.M., Randen, I., Juul, N.O. & Pettersen, E.O.: Is actin accumulation restricted to G1? Biochem. Soc. Trans. 15 (1987) 856-857.
  59. Jacobsen, A.B., Fosså, S.D., Lunde, S., Melvik, J.E. & Pettersen, EO.: Flow cytometric DNA measurements in paraffin embedded bladder carcinoma tissue before and after precystectomy radiotherapy. A preliminary report. Radiother. Oncol. 10 (1987) 149-155.
  60. Dornish, J.M., Pettersen, E.O. & Oftebro, R.: Synergistic cell inactivation of human NHIK 3025 cells by cinnamaldehyde in combination with cis-dichlorodiammineplatinum(II). Cancer Res. 48 (1988) 938-942.
  61. Jacobsen, A.B., Thorud, E., Fosså, S.D., Lunde, S., Shoaib, M.C., Juul, N.O. & Pettersen, E.O.: DNA flow cytometry in metastases and a recurrency of malignant melanomas. A comparison of results from fresh and paraffin embedded material. Virchovs Archives 54 (1988) 273-277.
  62. Sæther, G., Schwarze, P.E., Nesland, J.M., Juul, N.O., Pettersen, E.O. & Seglen, P.O.: The polyploidizing growth pattern of normal rat liver is replaced by divisional, diploid growth in hepatocellular nodules and carcinomas. Carcinogenesis 9 (1988) 939-945.
  63. Jacobsen, A.B., Fosså, S.D., Thorud, E., Lunde, S., Melvik, J.E. & Pettersen, E.O.: DNA flow cytometric values in bladder carcinoma biopsies obtained from fresh and from paraffin embedded material. APMIS 96 (1988) 25-29.
  64. Melvik, J.E. & Pettersen, E.O.: Oxygen and temperature dependent cytotoxic and radiosensitizing effect of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro. Radiat. Res. 114 (1988) 489-499.
  65. Nygaard, M.E.H., Dornish, J.M., Pettersen, E.O. & Oftebro, R.: Sulfhydryl-related reduction of the mitotic inhibition and cell inactivation induced by pyrimidine analogs. Anti-Cancer Drug Design 3 (1988) 15-24.
  66. Dornish, J.M., Undheim, K., Pettersen, E.O., Oftebro, R. & Laland, S.G.: Combination effects of cis-dichlorodiammineplatinum with selected metahalones, pyrimidine sulfoxides and pyrimidine sulfones on human NHIK 3025 cells in vitro. Anti-Cancer Drug Design 3 (1988) 191-198.
  67. Davies, C. deL., Pettersen, E.O. & Lindmo, T.: Changes in antigen expression on human FME melanoma cells after exposure to hypoxia and acidic pH, alone or in combination. Int. J. Cancer 43 (1989) 350-355.
  68. Alho, A., Eeg-Larsen, T., Melvik, J.E. & Pettersen, E.O.: Growth stimulation by gigant cell tumor of bone - A case report. Acta Orthop. Scand. 60 (1989) 227-229.
  69. Dornish, J.M., Pettersen, E.O. & Oftebro, R.: Modifying effect of cinnamaldehyde and cinnamaldehyde derivatives on cell inactivation and cellular uptake of cis-diamminechloroplatinum(II) in human NHIK 3025 cells. Cancer Res. 49 (1989) 3917-3921.
  70. Dornish, J.M. & Pettersen, E.O.: Modulation of cis-diammineplatinum(II)-induced cytotoxicity by benzaldehyde derivatives. Cancer Lett., 46 (1989) 63-68.
  71. Fosså, S.D., Melvik, J.E., Juul, N.O., Pettersen, E.O. & Theodorsen, L.: DNA flow cytometry in sperm cells from unilaterally orchiectomized patients with testicular cancer before further treatment. Cytometry 10 (1989) 345-350.
  72. Dornish, J.M. & Pettersen, E.O.: Potentiation of cis-dichlorodiammineplatinum(II)-induced cytotoxicity by methylglyoxal. Anticancer Res. 9 (1989) 1137-1142.
  73. Jacobsen, A.B., Lunde, S., Ous, S., Melvik, J.E., Pettersen, E.O., Kaalhus, O. & Fosså, S.D.: Multivariate analysis in 121 patients with T2/T3 bladder carcinomas treated with definitive radiotherapy with emphasis on flow cytometric DNA ploidy values. A paraffin embedded tumour tissue. Int. J. Radiol. Oncol. Biol. Phys. 17 (1989) 923-929.
  74. Tveit, K.M., Kærn, J., Høifødt, H.K., Pettersen, E.O., Abeler, V., Davy, M., Hannisdal, E. & Tropé, C.: Colony-forming ability of human ovarian carcinomas in the Courtenay soft agar assay. Anticancer Res. 9 (1989) 1577-1582.
  75. Dornish, J.M., Larsen, Rolf O., Schwarze, P.E., Børretzen, B. & Pettersen, E.O.: In vivo and in vitro pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats. Invest. New Drug 8 (1990) 149-157.
  76. Tanum, G., Tveit, K.M., Høst, H. & Pettersen, E.O.: Benzylidene-glucose: No effect after all? Am. J. Clin. Oncol., 13 (1990) 161-163.
  77. Dornish, J.M & Pettersen, E.O.: Requirement of a reactive aldehyde moiety for aldehyde-mediated protection against cis-dichlorodiammineplatinum-induced cell inactivation. Biochem. Pharmacol. 39 (1990) 309-318.
  78. Jacobsen, A.B., Nesland, J.M., Fosså, S.D. & Pettersen, E.O.: Human chorionic gonadotropin, neuron specific enolase and DNA flow cytometry in patients with high grade bladder carcinoma. J. Urology 143 (1990) 706-709.
  79. Juul, M.E.H., Dornish, J.M., Juul, N.O., Pettersen, E.O. & Oftebro, R.: Effect of two pyrimidine analogs on accumulation of tubulin in NHIK 3025 cells. Molec. Cell. Biochem. 96 (1990) 117-126.
  80. Kaern, J.M., Tropé, C.,Kjørstad, K.E., Abeler, V. & Pettersen, E.O.: Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol. Oncol. 38 (1990) 452-457.
  81. Juul, M.E.H., Dornish, J.M., Schwarze, P.E., Pettersen, E.O. & Oftebro, R.: Multipolar mitotic cells in the human cell line NHIK 3025 following treatment with the mitotic inhibitor NY 4137. Invest. New Drugs 9 (1991) 19-28.
  82. Fosså, S.D., Melvik, J.E., Juul, N.D., Pettersen, E.O., Åmellem, Ø. & Theodorsen, L.: DNA flow cytometry in sperm cells from testicular cancer patients. Eur. Urol. 19 (1991) 125-131.
  83. Åmellem, Ø & Pettersen, E.O.: Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the possible role of cell cycle arrest as a protection against hypoxia-induced lethal damage. Cell Prolif. 24 (1991) 127-141.
  84. Fosså, S.D., Nesland, J.M., Wæhre, H., Åmellem, Ø. & Pettersen, E.O.: DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I. Cancer 67 (1991) 1874-1877.
  85. Jacobsen, A.B., Tveit, K.M., Pettersen, E.O., Fosså, S.D. & Ous, S.: Colony-formation in urine bladder carcinoma. Relationship to DNA flow cytometry, stage and histopathology. Anticancer Res. 11 (1991) 777-782.
  86. Pettersen, E.O., Larsen, R.O., Børretzen, B., Dornish, J.M. & Oftebro, R.: Increased effect of benzaldehyde by exchanging the hydrogen in the formyl group with deuterium. Anticancer Res. 11 (1991) 369-374.
  87. Pettersen, E.O., Larsen, R.O., Børretzen, B., Dornish, J.M. & Oftebro, R.: Effect on protein synthesis and cell survival of the benzaldehyde derivatives sodium benzylidene ascorbate (SBA) and the deuterated compound zilascorb (2H). Anticancer Res. 11 (1991) 1977-1982.
  88. Åmellem, Ø. & Pettersen, E.O.: The role of protein accumulation on the kinetics of entry into S phase following extreme hypoxia. Anticancer Res. 11 (1991) 1983-1988.
  89. Fosså, S.D., Nesland, J.M., Pettersen, E.O., Åmellem, Ø., Wæhre, H. & Heimdal, K.: DNA ploidy in primary testicular cancer. Br. J. Cancer 64 (1991) 948-952.
  90. Jacobsen, A.B., Pettersen, E.O., Åmellem, Ø., Berner, A., Ous, S. & Fosså, S.D.: The prognostic significance of deoxyribonucleic acid flow cytometry in muscle invasive bladder carcinoma treated with preoperative irradiation and cystectomy. J. Urol. 147 (1992) 34-37.
  91. Jacobsen, A:B., Berner, A., Juul, M.E.H., Ous, S., Pettersen, E.O. & Fosså, S.D.: DNA flow cytometry and neo-adjuvant chemotherapy/radiotherapy in operable muscle-invasive badder carcinoma. Eur. Urol. 22, (1992) 316-322.
  92. Melvik, J.E., Dornish, J.M., Larsen, R.O., Børretzen, B., Oftebro, R. & Pettersen, E.O.: In vitro modulating effect of the reversible protein synthesis inhibitor zilascorb(2H) on cis-diamminedichloro platinum(II)-induced cytotoxicity. Anticancer Res. 12 (1992) 33-38.
  93. Nordal, A.K., Juul, N.O. & Pettersen, E.O.: Protein accumulation in lethally damaged cells after treatment with cis-dichlorodiammineplatinum(II): Hazard to effect studies as based on inhibition of volume growth. Anticancer Res. 12 (1992) 305-312.
  94. Wæhre, H., Åmellem, Ø., Stenwig, A.E., Tverå, K., Juul, M., Pettersen, E.O. & Fosså, S.D.: DNA cytometry and histological findings before and after 125I implantation of primary prostate cancer. J. Urol. 148 (1992) 838-842.
  95. Fosså, S.D., Berner, A., Heiden, T., Juul, M.E.H., van den Ouden, D., Pettersen, E.O., Wang, N. & Tribukait, B.: DNA ploidy in cell nuclei from paraffin-embedded material - comparison of results from two laboratories. Cytometry 13 (1992) 395-403.
  96. Kærn, J., Wetterland, J., Tropé, C.G., Farrants, G.W., Juhng, S.W., Pettersen, E.O., Reith, A. & Danielsen, H.E.: Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer. Cytometry 13 (1992) 314-321.
  97. Kærn, J., Iversen, T., Tropé, C., Pettersen, E.O. & Nesland, J.M.: Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: an important prognostic method. Int. J. Gynecol. Cancer. 2 (1992) 169-174.
  98. Melvik, J.E., Dornish, J.M. & Pettersen, E.O.: The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro. Br. J. Cancer 66 (1992) 260-265.
  99. Melvik, J.E., Dornish, J.M., Tonini, G.P. & Pettersen, E.O.: Characterization of a human cell line of cervix carcinoma origin, NHIK 3025/DDP, resistant to cis-diamminedichloroplatinum(II). Cell. Pharmacol. 1 (1993) 9-16.
  100. Dunsæd, C.B., Dornish, J.M., Aastveit, T.E. & Pettersen, E.O.: In vitro pharmacokinetics of the antitumour agent 4.6-benzylidene-D-glucose (BG) and the deuterated analog 4.6-benzylidene-d1-D-glucose (P-1013) in mice, rats and dogs. Int. J. Oncol. 2, (1993) 61-66.
  101. Shi, Y., Åmellem, Ø. & Pettersen, E.O.: Hypoxia associated proteins in human cells cultivated in vitro: Lack of association with hypoxia induced cell cycle regulation? APMIS 101 (1993) 75-82.
  102. Åmellem, Ø. & Pettersen, E.O.: Cell cycle progression in human cells following reoxygenation after extreme hypoxia: consequences concerning initiation of DNA synthesis. Cell Prolif. 26 (1993) 25-35.
  103. Pettersen, E.O., Larsen, R.O., Dornish, J.M., Børretzen, B., Juul, M.E.H., Aastveit, T.E., Nesland, J.M., Rofstad, E.K. & Oftebro, R.: Tumour necrotization in nude mice xenografts by the reversible protein synthesis inhiibitor zilascorb(2H). Br. J. Cancer 67 (1993) 650-656.
  104. Vergote, I.B., Kærn, J., Abeler, V.M. Pettersen, E.O., de Vos, L.N. & Tropé, C.G.: Analysis of prognostic factors in stage I epithelial ovarian carcinoma. Importance of degree of differentiation and DNA ploidy in predicting relapse. Am. J. Obstet. Gynecol. 169 (1993) 40-52.
  105. Berner, A., Danielsen, H.E., Juul, N.O., Juul, M.E.H., Pettersen, E.O., Reith, A., Nesland, J.M. & Fosså, S.D.: Caveats in the estmation of DNA plody in paraffin embedded specimens of primary prostate cancer and lymph node metastases by flow- and image cytometry. Anal Cell. Pathol. 5 (1993) 339-352.
  106. Berner, A., Danielsen, H.E., Pettersen, E.O., Fosså, S.D. & Nesland, J.M.: DNA distribution in the prostate. Normal gland, benign and premalignant lesions, and subsequent adenocarcinomas. Anal. Quant. Cytol. Histol. 15 (1993) 247-252.
  107. Fosså, S.D., Berner, A., Jacobsen, A.B., Wæhre, H., Kvarstein, B., Urnes, T., Øgreid, P., Bjerklund Johansen, T.E., Silde, J., Nesland, J.M. & Pettersen, E.O.: Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer. Br. J. Cancer 68 (1993) 572-578.
  108. Kærn, J., Tropé, C.G., Kristensen, G.B., Abeler, V.M. & Pettersen, E.O.: DNA ploidy; the most important prognostic factor in patients with borderline tumours of the ovary. Int. J. Gynecol. Cancer. 3 (1993) 349-348.
  109. Ottestad, L., Pettersen, E.O., Nesland, J.M., Hannisdal, E., Fosså, S.D. & Tveit K.M.: Flow cytometric DNA analysis as a prognostic factor in human breast carcinoma. Pathol. Res. Pract. 189 (1993) 405-410.
  110. Alho, A., Skjeldal, S., Melvik, J.E., Pettersen, E.O. & Larsen, T.E.: The clinical importance of DNA synthesis and aneuploidy in bone and soft tissue tumors. Anticancer Res. 13 (1993) 2383-2388.
  111. Kærn, J., Tropé, C.G., Kristensen, G.B., Tveit, K.M., & Pettersen, E.O.: Evaluation of DNA ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma - a prospective study. Am J. Obstet. Gynecol. 170 (1994) 479-487.
  112. Kærn, J., Tropé, C.G., Kristensen, G.B. & Pettersen, E.O.: Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma. Cancer 73 (1994) 1870-1877.
  113. Alho, A., Skjeldal, S. Pettersen, E.O., Melvik, J.E. & Larsen, T.E.: Aneuploidy in benign tumors and nonneoplastic lesions in musculoskeletal tissues. Cancer 73 (1994) 1200-1205.
  114. Fosså, S.D., Silde, J., Theodorsen, L. & Pettersen, E.O.: Pre-treatment DNA ploidy of sperm cells as a predictive parameter of post-treatment spermatogenesis in patients with testicular cancer. Br. J. Urol. 74 (1994) 359-365.
  115. Åmellem, Ø., Löffler M. & Pettersen, E.O.: Reguation of cell proliferation under extreme and moderate hypoxia: The role of pyrimidine(deoxy)nucleotides. Br. J. Cancer 70 (1994) 857-866.
  116. Kristensen, G.B., Kærn, J., Abeler, V.M., Hagmar, B., Tropé, C.G. & Pettersen, E.O.: No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction incancer o the uterine crvix: A prospective study of 465 patients. Gynecol. Oncol. 57 (1995) 79-85.
  117. Scheistrøen, M., Tropé, C., Kærn, J., Pettersen, E.O., Abeler, V.M. & Kristensen, G.B.: Malignant melanoma of the vulva. Evaluation of prognostic factors with emphasis on DNA ploidy in 75patients. Cancer 75 (1995) 72-80.
  118. Akudugu, J.M., Olsen, D.R., Skretting, A., Pettersen, E.O. & Reitan, J.B.: In vitro soft agar model for experimental brachyterapy: Absorbed dose measurements. Endocurietherapy/Hyperthermia Oncology 12 (1995) 51-61.
  119. Dunsæd, C.B., Dornish, J.M. & Pettersen, E.O.: The bioavailability and dose-dependency of the deuterated antitumour agent 4,6-benzylidene-d1-D-glucose (P-1013) in mice and rats. Cancer Chemother. Pharmacol. 35, (1995) 464-470.
  120. Kraggerud, S.M., Sandvik, J.A. & Pettersen, E.O.: Regulation of protein synthesis in human cells exposed to extreme hypoxia. Anticancer Res. 15 (1995) 683-686.
  121. Dunsæd, C.B., Dornish, J.M., Aastveit, T.E., Nesland, J.M. & Pettersen, E.O.: Growth inhibition of human tumour xenografts in nude mice by treatment with the antitumour agent 4,6-benzylidene-d1-D-glucose (P-1013). Anti-Cancer Drugs 6 (1995) 456-464.
  122. Nordal, R.R., Kristensen, G.B., Stenwig, A.E., Pettersen, E.O. & Tropé, C.G.: The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Onologica 3 (1995) 797-802.
  123. Dunsæd, C.B., Dornish, Oftebro, R. & Pettersen, E.O.: Effect on cell survival and protein synthesis of benzylidene-glucose (BG) and the deuterated analogue P-1013 in cultured cells. Anticancer Res 15 (1995) 1921-1928.
  124. Scheistrøen, M., Tropé, C., Kærn, J., Abeler, V.M., Pettersen, E.O., & Kristensen, G.B.: Malignant melanoma of the vulva FIGO stage I. Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment. Gynecologic Oncology 61 (1996) 253-258.
  125. Nordal, R.R., Kristensen, G.B., Kærn, J., Stenwig, A.E., Pettersen, E.O., & Tropé, C.G.: The prognostic significanse ofsurgery, tumor size, malignancy grade, menopausal status and DNA ploidy in endometrial stromal sarcoma. Gyn Oncol. 62 (1996) 254-259.
  126. Pettersen, E.O., Wang, H.: Radiation sensitizing effect of oxygen in synchronized cells pretreated with acute or prolonged hypoxia. Int. J. Radiat. Biol. 70 (1996) 319-326.
  127. Karlsen, F., Kalantari, M., Jenkins, A., Pettersen, E.O., Kristensen, G., Holm, R., Johansson, B. & Hagmar, B.: Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin. Microbiol. 34 (1996) 2095-2100.
  128. Åmellem, Ø., Stokke, T., Sandvik, J.A. & Pettersen, E.O.: The retinoblastoma gene product is reversibly dephosphorylated and bound in the nucleus in S and G2 phase during hypoxic stress. Exp. Cell Res. 227 (1996) 106-115.
  129. Scheistrøen, M., Tropé, C., Kærn, J., Pettersen, E.O., Alfsen, G.C. & Nesland, J.M.: DNA ploidy expression of p53 and C-erb-2 in extramammary paget's disease of the vulva. Gynecol. Oncology 64 (1997) 88-92.
  130. Åmellem, Ø., Stokke, T., Sandvik, J.A., Smedshammer, L. & Pettersen, E.O.: Hypoxia induce apoptosis in human cells with normal p53 status and function, without any alteration in the nuclear protein level. Exp. Cell Res. 232 (1997) 361-370.
  131. Nordal, R.R., Kristensen, G.B., Stenwig, A.E., Nesland, J.M., Pettersen, E.O., & Trope, C.G.: An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol. Oncol. 67 (1997) 316-321.
  132. Lopes, J.M., Bruland, Ø.S., Bjerkhagen, B., Silva, M.C., Holm, R., Pettersen, E.O., Solheim, Ø.P., Sobrinho-Simões, M. & Nesland, JM.: Synovial sarcoma. Immunohistochemical expression of P-glycoprotein and glutathione S treansferase-pi and clinical drug resistance. Patol. Res. Pract. 193 (1997) 21-36.
  133. Åmellem, Ø., Stokke, T., Sandvik, J.A., Karlsen, F. & Pettersen, E.O.: The retinoblastoma protein-associated cell-cycle arrest in S-phase under moderate hypoxia is disrupted in cells expressing HPV 18 E7 oncoprotein. Br. J. Cancer . 77 (1998) 862-872.
  134. Lopes, J.M., Hannisdal, E.H., Bjerkhagen, B., Bruland, Ø.S., Danielsen, H.E., Pettersen, E.O., Sobrinho-Simões, M. & Nesland, JM.: Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers. Ann. Cell Pathol. 16, (1998) 45-62.
  135. Koritzinsky, M., Furre, T., Åmellem, Ø. & Pettersen, E.O.: Radiation response of synchronized human NHIK 3025 cells irradiated aerobically following a prolonged treatment with extremely hypoxic conditions. Int. J Radiat. Biol. 74, (1998) 491-500.
  136. Kraggerud,S.M., Berner, A., Bryne, M., Pettersen, E.O., & Fosså, S.D.: Spermatocytic seminoma as compared to classical seminoma: An immunohistochemical and flowcytometric study. APMIS 107 (1999) 297-302.136.
  137. Sagvolden, G., Giaever, I., Pettersen, E.O. & Feder, J.: Cell adhesion force microscopy. Proc. Natl Acad. Sci. 96, (1999) 471-476.
  138. Scheistrøen, M., Tropé, C., Pettersen, E.O. & Nesland, J.M.: p53 protein expression in squamous cell carcinoma of the vulva. Cancer. 85, (1999) 1133-1138.
  139. Furre, T., Bergstrand, E.S., Pedersen, E. Koritzinsky, M. Olsen, D.R. Hole, E.O. & Pettersen, E.O.: Measurement of dose rate at the interphase of cell culture medium and glass dishes by means of ESR dosimetry using thin films of alanine. Radiation Res. 152, (1999) 76-82.
  140. Furre, T., Koritzinsky, M., Olsen, D.R. & Pettersen, E.O.: Inverse dose-rate effect due to pre-mitotic accumulation during continuous low dose rate irradiation of cervix carcinoma cells. Int. J. Radiat. Biol. 75, (1999) 699-707.
  141. Tropé, C, Kaern, J., Hogberg, T. Abeler, V. Hagen, B., Kristensen, G. Onsrud, M. Pettersen, E., Rosenberg, P. Sandvei, R., Sundfor, K. and Vergote, I.: Randomized study on adjuvant chemotherapy in stage I high risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Annals of Oncology. 11 (2000) 281-288.
  142. Ebbesen, P., Pettersen, E.O., Denekamp, J., Littbrand, B., Keski-Oja, J., Schousboe. A., Sonnewald, U., Åmellem, Ø., amnd Zachar, V.: Hypoxia, normoxia and hyperoxia. Terminology for medical in vitro cell biology. Acta Oncologica 39 (2000) 247-248.
  143. Alfsen, G.C., Kristensen, G.B., Skovlund, E., Pettersen, E.O. & Abeler, V.M.: Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix. A population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer 92 (2001) 2471-2483.
  144. Cunderlikova, B., Bjørklund, E., Pettersen, E.O., Moan, J.E.: Ph-dependent spectral properties of HpIX, TPPS2A, mTHPP and mTHPC. Photochemistry and Photobiology. 74 (2001) 246-252.
  145. Koritzinsky, M., Wouters, B.G., Åmellem, Ø., Pettersen, E.O.: Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. Int. J. Radiat. Biol. 77 (2001) 319-328.
  146. Tropé, C.G.; Kaern, J.; Hogberg, T.; Abeler, V.; Hagen, B.; Kristensen, G.; Onsrud, M.; Pettersen, E.O.; Rosenberg, P.; Sandvei, R.; Sundfor, K.; Vergote, I.: Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. - Int. J. Gynecol. Oncol. 11 (Suppl 1) (2001) 20.
  147. Graff, P., Åmellem, Ø., Andersson, K. K. & Pettersen, E. O.: Role of ribonucleotide reductase in regulation of cell cycle progression during and after exposure to moderate hypoxia. Anticancer Research 22 (2002) 59-68.
  148. Røtterud, R., Pettersen, E.O., Berner, A., Holm, R. & Fosså, S.D.: Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients. Acta Radiologica 41 (2002) 463-470.
  149. Furre, T., Eggen, I., Koritzinsky, M., Åmellem, Ø. and Pettersen, E.O.: Lack of inverse dose rate effect and binding of the retinoblastoma gene product in the nucleus of human cancer T-47D cells arrested in the G2 by ionizing radiation. Int. J. Radiat. Biol. 79 (2003) 413-422.
  150. Friberg, E.G; Cunderlikova, B; Pettersen, E.O; Moan, J.. pH effects on the cellular uptake of four photosensitizing drugs evaluated for use in photodynamic therapy of cancer. Cancer Letters 195 (2003) 73-80.
  151. Seim, J., Graff, P., Åmellem, Ø., Landsverk, K.S., Stokke, T., Pettersen, E.O.: Hypoxia-induced irreversible S phase arrest involves down-regulation of cyclin A. Cell Prolif. 36 (2003) 321-332.
  152. Graff, P., Seim, J., Åmellem, Ø., Arakawa, H., Nakumura, Y., Andersson, K. K., Stokke, T. and Pettersen, E. O.: Counteraction of pRB-dependent protection after extreme hypoxia by elevated ribonucleotide reductase. Cell Prolif. 37 (2004) 367-383.
  153. Ebbesen, P., Eckardt, K.U., Ciampor, F., & Pettersen, E.O.: Linking measured intercellular oxygen concentrations to human cell functions. Acta Oncol. 43 (2004) 598-600.
  154. Graff, P,. Åmellem, Ø., Seim, J., Stokke, T., & Pettersen, E.O.: The role of p27 in controlling the oxygen-sensitive checkpoint of mammalian cells in late G1 Anticancer Res 25 (2005) 2259-2268.
  155. Pettersen, E.O., Larsen, L.H., Ramsing, N.B. and Ebbesen, P: Pericellular oxygen depletion during ordinary tissue culturing measured with oxygen microelectrodes. Cell prolif. 38 (2005) 257-267.
  156. Edin, N.J., Olsen, D.R., Stokke, T. & Pettersen, E.O.: Recovery of low-dose hyper-radiosensitivity following a small priming dose depends on priming dose-rate. Int. J. Low Radiat. 4 (2007) 69-86.
  157. Hanish, P.H., Furre, T., Olsen, D.R. & Pettersen, E.O.: Radiobiological responses for two cell lines following continuous low dose-rate (CLDR) and pulsed dose rate (PDR) brachytherapy. Acta Oncologica 46 (2007) 602-611.
  158. Pettersen, E.O., Bjørhovde, I., Søvik, Å., Edin, N.F.J., Zachar, V., Hole, E.O., Sandvik, J.A. & Ebbesen, P.: Response of chronic hypoxic cells to low dose-rate irradiation. Int. J. Radiat. Biol. 83 (2007) 331-345.
  159. Edin, N.J., Sandvik, J.A., Olsen, D.R. & Pettersen, E.O.: The elimination of low-dose hyper-radiosensitivity by transfer of irradiated cell conditioned medium depends on dose-rate. Radiat. Res. 171 (2009) 22-32.
  160. Ebbesen,P., Pettersen, E.O., Gorr, T., Jobst, G., Williams, K., Kieninger, J., Wenger, R., Pastorekova, S., Dubois, L., Lambin, P., Wouters, B.G., Supuran, C., Poellinger, L., Ratcliffe, P., Kanopka, A., Görlach, A., Gasmann. M., Harris, A., Maxwell, P. & Scozzafava, A.: Taking advantage of tumour cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J. Enzym Inhib. Med. Chem. 24 (S1) (2009) 1-39.
  161. Edin N.J., Olsen, D.R., Stokke, T., Sandvik, J.A., Ebbesen, P. &Pettersen, E.O.: Mechanisms of the elimination of low dose hyper-radiosensitivity in T-47D cells by low dose-rate priming. Int. j. Radiat. Biol. 85 (2009) 1157-1165.

Invited articles and book chapters

  1. Pettersen, E.O., Oftebro, R. & Brustad, T.: The radiosensitivity of human cells, cultivated in vitro, under aerobic and extremely hypoxic conditions, in the presence and absence of TMPN. I. In: Proceedings of the Seventh Nordic Meeting on Clinical Physics, Jahren, R. (ed.). p. 1-10. The Norwegian Radium Hospital, Oslo (1973). 2.
  2. Bøyum, A., Pettersen, E.O., Laane, B. & Carsten, A.L.: The diffusion chambertechnique as progenitor (stem) cell assay. In: Proceedings of Second International Workshop on Hemopoiesis in Culture. Robinson, W.A. (ed.). p. 149-159. DHEW Publication No (NIH) 74-205, New York (1973).
  3. Pettersen, E.O., Wibe, E., Løvhaug, D., Oftebro, R. & Brustad, T.: Effects of oxygen and TMPN on the initial part of the dose-effect curves of human cells in culture. In: Cell Survival after Low Doses of Radiation. Alper, T. (ed.) p. 150-157. John Wiley & Sons, London (1975).
  4. Lindmo, T., Steen, H.B. & Pettersen, E.O.: Cell cycle progression after X-ray irradiation of synchronized populations of NHIK 3025 cells. In: Third International Symposium Pulse Cytophotometry. Lutz, D. (ed.) European Press, Ghent, 1978, 303-310.
  5. Bakke, O., Pettersen, E.O., Lindmo, T. & Oftebro, R.: Cell cycle characteristics of synchronized and non-synchronized populations of human cells in vitro. In: Biomathematics and Cell Kinetics. Valleron, A.J. (ed.) Elsevier, Amsterdam, 1978 pp. 423-430.
  6. Rønning, Ø.W., Lindmo, T., Pettersen, E.O. & Seglen, P.O.: Kinetics of entry into S-phase and into the G1-phase of the subsequent cell cycle for synchronized NHIK 3025 cells. In: Flow Cytometry IV. Lærum, O.D., Lindmo, T. & Thorud, E. (eds.) Universitetsforlaget, Oslo, 1980 pp. 350-353.
  7. Rønning, Ø.W., Lindmo, T., Pettersen, E.O. & Seglen, P.O.: Cell cycle traverse in relation to protein content. In: Progress in cell cycle controls. (eds. J. Chaloupka, A. Kotyk, E. Streiblova), Praha 1983. pp 106-118.
  8. Jacobsen, A.B., Fosså, S.D., Lunde, S., Melvik, J.E. & Pettersen, E.O.: Flow cytometric DNA measurements in paraffin embedded bladder carcinoma tissue before precystectomy radiotherapy. A preliminary report. Clinical Cytometry and Histometry (G. Burger, J.S. Ploem and K. Goertler, eds.), Academic Press, 1987, pp. 447-449.
  9. Melvik, J.E. & Pettersen, E.O.: Temperature-dependent radiosensitization by cis-diamminedichloroplatinum(II) on human NHIK 3025 cells in vitro. Proc. of the 12th Nordic Meeting on Clinical Physics. April, 1986. (P. Holmberg and R. Jahren, eds.)(1988) 56-69.
  10. Tropé, C.G. Kærn, J. Kristensen, G. Abeler, V. & Pettersen, E.O.: Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. A second look. In: Das Ovarialkarzinom. 1 Tumorbiologie, Screening, Staging. (H-G Meerpohl, A Pfleiderer & Chr Z Profous, Eds) Springer Verlag, Berlin, Heidelberg, NY, London, Paris, Tokyo, Hong Kong, Barcelona, Budapest, 1993, pp 90-110.
  11. Vergote, I.B., Tropé, C.G., de Vos, L.N. Kærn, J., Abeler, V.M., Winderen, M. & Pettersen, E.O.: Adjuvant treatment of ovarian carcinoma. In: Cancer treatment. An update. Ed P. Banzet, J.F. Holland, D. Khayat and M. Weil, Springer Verlag France, Paris, 1994 pp 464-468.
  12. Trope, C., Kærn, J., Abeler, V., Kristensen, G., Makar, A., Vergote, I. & Pettersen, E.O.: The importance of DNA as a prognostic factor in ovarian borderline and stage I cancer. In: The Management of Adnexal Cysts. M.A. Bruhat, Ed. Blackwell Scientific Publications, London (1994) pp19-27.
  13. Pettersen, E.O., Wang, H., Åmellem, Ø. & Sandvik J.A: Radiobiologiske studier av celler i kultur. Tanker omkring, og målinger av, oksygeneffekten. In: Jubileumsseminar, NTH's studieretning for Biofysikk og Medisinsk Teknologi, 25 år. Norges Tekniske Vitenskapsakademi i samarbeid med Institutt for Fysikk, NTH, 1995. pp 59-67.
  14. Kærn, J., Tropé, C.G., Abeler, V. & Pettersen, E.O.: Cellular DNA content: the most important prognostic factor in patients with borderline tumors of the ovary. Can it prevent overtreatment? In: Ovarian cancer 3. (Frank Sharp, Peter Mason, Tony Blackett and Jonathan Berek eds) ISBN 0 412 57000 9 Chapman & Hall, London, (1995).
  15. Torgersen, R., Pettersen, E.O. & Vistnes, A.I.: Influence of extremely low frequency (ELF) magnetic fields on in vitro cell growth. Short paper presented at 5th Nordic Workshop on Biological Effects of Low Frequency Electromagnetic Fields. Trondheim April 1997.
  16. Pettersen, E.O.: Barn og angst for ioniserende stråling - en kreftforskers syn. Tidsskriftet Barn, Utgitt av Norsk senter for Barneforskning, 2 (1997) 46-56.
  17. Tropé, C.; Kaern, J.; Hogberg, T.; Abeler, V.; Hagen, B.; Kristensen, G.; Onsrud, M.; Pettersen, E.O.; Rosenberg, P.; Sandvei, R.; Sundfor, K.; Vergote, I.; Dnr Randomized Study on Adjuvant Chemotherapy in Stage I High Risk Ovarian Cancer with Evaluation of DNA-ploidy as Prognostic Instrument. A Nordic Ovarian Cancer Group Trial. -- State of the Art in the Treatment of Ovarian Cancer Grupo Espanol de Investigatiò en Cancer Ginecològico El Escorial, Madrid, Spain. 1999-11-05: 15-17.
  18. Pettersen, E.O.: Virkningen av ioniserende stråling på mennesker og andre levende skapninger -- NOU 2001: 30. Vurdering av strategier for sluttlagring av høyaktivt reaktorbrensel. (ISBN 82-583-0616-2) (ISSN 0333-2306) Statens forvaltningstjeneste, Informasjonsavdelingen. 2001-12 : pp 75-78.
  19. Pettersen, E.O. Adaptive response. In: Radiation at home, outdoors and in the workplace: Scandinavian Science Publisher 2001. ISBN 82-91833-02-8. pp. 45-51.
  20. Pettersen, E.O. Low-dose hypersensitivity and adaptive responses to radiation. In: Natural Ionizing Radiation and Health: (B. Bølviken Ed.) The Norwegian Academy of Science and Letters, 2002, ISBN: 82-7099-368-9 pp 92-102.

Patents:

  1. Børretzen, B., Larsen, R.O., Pettersen, E.O., Dornish, J.M. & Oftebro, R.: Anticancer compounds, US Patent 4,874,780, 17 Oct 1989.
  2. Børretzen, B., Larsen, R.O., Dornish, J.M., Oftebro, R. & Pettersen, E.O.: Anticancer agent comprising L-ascorbic acid and O-benzylidene-L-ascorbic acid or deuterated derivatives. UK Patent GB 2 208 798 B (1991)
  3. Oftebro, R., Pettersen, E.O., Dornish, J.M., Børretzen, B. & Larsen, R.O.: Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment. United States Patent no 5,049,396 (1991).
  4. Oftebro, R., Pettersen, E.O., Dornish, J.M., Børretzen, B. & Larsen, R.O.: Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer. United States Patent no 5,130,145 (1992).
  5. Pettersen, E.O., Larsen, R.O., Børretzen, B., Dornish, J.M., & Oftebro, R.: Cyclic (hetero)acetals of nitro substituted benzaldehydes having anti-cancer actvity. European Patent Application EP 0 493 883 A1 (1992).
  6. Pettersen, E.O., Larsen, R.O., Dornish, J.M., Børretzen, B., Oftebro, R. & Ramdahl, T.: Anticancer benzaldehyde compounds. European Patent Application EP 0 552 880 A1 (1993).
  7. Pettersen, E.O., Larsen, R.O., Dornish, J.M., Børretzen, B., Oftebro, R. & Ramdahl, T.: Deuterated benzaldehydes. United States Patent no 5,324,859 (1994).
  8. Pettersen, E.O., Larsen, R.O., Dornish, J.M., Børretzen, B., Oftebro, R. & Ramdahl, T.: Benzaldehydacetal-derivater med virkning mot abnormalt økt celleproliferasjon og kreft. Patent No 302820, meddelt 27.4.1998.
  9. Børretzen, B., Moen, V., Larsen, R.O., Pettersen, E.O., Dunsæd, C.B. & Sagvolden, G.: Chemical compounds. Patent application of Feb 1999. (patent application no. 19990814, Norway).
  10. Børretzen, B., Moen, V., Larsen, R.O., Pettersen, E.O. & Dunsæd, C.B.: Chemical compounds. Patent application of 5. July 1999 (P 9951).
  11. Børretzen, B., Moen, V., Larsen, R.O., Pettersen, E.O., Dunsæd, C.B. & Sagvolden, G.: Chemical compounds. International application published under the patent cooperation treaty (WO 00/48609, PCT/NO00/00059) 11.01.2001
  12. Børretzen, B., Moen, V., Larsen, R.O., Pettersen, E.O., Dunsæd, C.B. & Sagvolden, G.: Chemical compounds. International application published under the patent cooperation treaty (WO 00/48610, PCT/NO00/00060) 11.01.2001
  13. Børretzen, B., Moen, V., Larsen, R.O., Pettersen, E.O., Dunsæd, C.B. 5-nitrofurfural derivatives. International application published under the patent cooperation treaty (PCT/NO00/00226) 11.01.2001.

Presentations at international meetings (only period 2000-2008 included)

  1. Pettersen, Erik O. Investigating pipeline products of zilascorb(2H) as cancer drugs [Lecture] Norsk Hydro Porsgrunn, Norway 31st March 2000.
  2. Pettersen, Erik O. Oxygenation and regulation of cell growth and cell cycling [Lecture]. The Nordic-Russian St. Petersbug workshop on cell biology and normoxia. St. Petersburg Russia 9th May 2000.
  3. Pettersen, Erik O. Deuterated benzylidene glucose, an overview. [Lecture] Norsk Hydro Porsgrunn, Norway 4th July 2000.
  4. Alfsen, Cecilie G.; Abeler, Vera M; Reed, Wenche; Kristensen, Gunnar B.; Skovlund, Eva; Pettersen, Erik O; Thoresen, Steinar Ø. Adenocarcinoma of the Uterine cervix. Incidence, Prognosis and Reproducibility of classification. [Lecture]. VII Meeting of the International Gynecologic Cancer Society. Buenos Aires, Argentina 22nd Oct 2000.
  5. Graff, Pål; Åmellem, Øystein; Andersson, K. Kristoffer; Pettersen, Erik O. Is ribonucleotide reductase an oncogene under moderate hypoxia? [Lecture]. Symposium on "Theoretical and practical aspects of in vivo and in vitro imitation of the environment of tumour cells in vivo"; Stockholm, Sweden 27th -28th Oct 2000.
  6. Pettersen, Erik O. Prolonged hypoxia and radiosensitivity [Lecture]. Symposium on "Theoretical and practical aspects of in vivo and in vitro imitation of the environment of tumour cells in vivo", Stockholm, Sweden 27th -28th Oct 2000.
  7. Kristensen, Gunnar B.; Kildal, Wanja; Abeler, Vera M; Pettersen, Erik O; Kaern, Janne; Trope, Claes Gøran; Vergote, Ignace B; Danielsen, Håvard E.. High resolution image cytometry. A better method to predict prognosis in early ovarian cancer. [Lecture]. SGO Annual Meeting. Published in Gynecologic Oncology vol 76(2) pp236 (2000).
  8. Pettersen, Erik O. The effect of P-1013 and other benzaldehyde derivatives in preclinical studies. [Lecture]. Presentation for Company Antisoma and Norsk Hydro on co-operative efforts in development of cancer drugs. London, UK, 3rd May 2001.
  9. Pettersen, Erik O. Effects of P-1013, P-1190 and P-1192 in cell cultures and human tumour xenografts in nude mice. [Lecture]. Meeting with company CNC and Norsk Hydro on co-operative efforts in development of cancer drugs. Paris France, 30th May 2001.
  10. Pettersen, Erik O. Low-dose hypersensitivity and adaptive effects. [Lecture]. Conference on Natural Ionizing Radiation and Health The Norwegian Academy of Science and Letters, Oslo 5th June 2001.
  11. Pettersen, Erik O. Effect of low-frequent magnetic fields in combination with hypoxia on human cells in vitro [Lecture]. Normoxia Symposium on "The Use of Oxygen Tension Control in Nordic Basic Research and Bioingeneering". First symposium of the EU network OXNORM (Optimising the oxygen tension for in vitro cell work). Oslo 6th-9th Sept 2001.
  12. Graff, Pål; Åmellem, Øystein; Andersson, K. Kristoffer; Pettersen, Erik O. Is Ribonucleotide Reductase an Oncoprotein under Moderate Hypoxia? [Lecture]. Normoxia Symposium on "The Use of Oxygen Tension Control in Nordic Basic Research and Bioingeneering". First symposium of the EU network OXNORM (Optimising the oxygen tension for in vitro cell work). Oslo 6th-9th Sept 2001.
  13. Pettersen, Erik O. Hypoxia in radiobiology and cell cycling. [Lecture]. Scientific planning meeting for future Nordic co-operation with Baltic countries (NORFA). Tartu University, Estonia 12th Jan 2002.
  14. Graff, Pål; Seim, Jo; Åmellem, Øystein; Andersson, K. Kristoffer; Pettersen, Erik O. Cell cycle regulation under hypoxia - a possible oncogenic effect of ribonucleotide reductase [Lecture]. Biofysikermøtet 2002 Kongsvoll 13th March 2002.
  15. Pettersen, Erik O. Range of oxygen concentrations in relation to cell respiration. [Lecture]. Second symposium of the EU network OXNORM (Optimising the oxygen tension for in vitro cell work). Copenhagen, Denmark 30th May 2002.
  16. Pettersen, Erik O. Oxygenation and regulation of cell growth and cell cycling. [Lecture]. Nordic Summer School of Angiogenesis and Oxygen Tension (Arrangement by University of Helsinki, Finland). Mariehamn, Åland Finland 29th July 2002.
  17. Pettersen, Erik O. Controlling oxygen tension in vitro. [Lecture]. NorFA Baltic Meeting on Cell Biology; Tartu, Estonia 22nd -25th May 2003.
  18. Pettersen, Erik O. Summing up of the 3 years of cooperation in the OXNORM EU study group [Lecture]. Third symposium of the EU network OXNORM (Optimising the oxygen tension for in vitro cell work). Bratislava, Slovakia 6th - 9th Nov 2003.
  19. Pettersen, Erik O. Effects of ionizing radiation and people´s fantasies concerning the effects of radiation. [Lecture]. Seminar series at Dept. of Stem Cell Res., Univ. of Aalborg; Århus, Denmark 18th Nov 2003.
  20. Pettersen, Erik O. Hypoxia: Physics and basic cell biology. [Lecture]. First General Meeting Concerning the Nordic Industrial Fund Project "Transferring Oxygen Biology to Companies". Copenhagen, Denmark 13th - 15th Feb 2004.
  21. Pettersen, Erik O. Effects of ionizing radiation on cells and consequences for effects on human populations. [Lecture] Seminar for Master level students at the University of Aalborg, Denmark. Århus, Denmark 21st Feb 2004.
  22. Pettersen, Erik O. The science of the research clusters of EUROXY and their interaction [Lecture]. First General Meeting of the EU-6th framework integrated project EUROXY; Copenhagen, Denmark 5th - 6th March 2004.
  23. Pettersen, Erik O. On the importance of measuring oxygen tensions in medium and consequences of long-term hypoxia on radiation responses to low dose-rate irradiation. [Lecture] Second cluster meeting of cluster I of the EU-6th framework integrated project EUROXY; Copenhagen, Denmark 8th May 2004 .
  24. Pettersen, Erik O. Oxygen control and measurement: Effect of prolonged hypoxia and low dose-rate irradiation on cells in culture. [Foredrag]. Euroxy, 3rd Cluster I meeting held in Maastricht, the Netherlands 28th Aug 2004.
  25. Pettersen. Erik O. Possible changes in cell responses following long-term hypoxia. [Foredrag]. 2nd General Meeting of the EU-6th framework integrated project EUROXY; Copenhagen, Denmark 16th - 18th Sept 2004.
  26. Pettersen, Erik O. Basic physics and biology of hypoxia. [Foredrag]. 2nd General Meeting Concerning the Nordic Industrial Fund Project "Transferring Oxygen Biology to Companies". Copenhagen, Denmark 28th - 30th Jan 2005.
  27. Pettersen, Erik O. A plan for the teaching activities in the coming years. 3rd General Meeting of 6th EU framework EUROXY in Florence, Italy; 26th -29th May 2005.
  28. Pettersen, Erik O. Towards new in vitro oxygen sensors. . [Foredrag] Joint Cluster I/III meeting of the EU-6th framework integrated project EUROXY; Brussels, Belgium 25th Nov 2005.
  29. Pettersen, Erik O. Extreme hypoxia at work [Foredrag]. 3rd General meeting in the Nordic Innovation Network; 26th - 27th Jan 2006.
  30. Pettersen, Erik O. Development of methodology for characterization and definition of appropriate in vitro oxygenation for cancer research. [Foredrag]. 4th General meeting of the EU-6th framevork ip, EUROXY; Bratislava, Slovakia, 8th - 10nd Feb 2006.
  31. Pettersen, Erik O. WP2 at 24 months: Effects of low oxygen and mild radiation on cell cycling and survival [Foredrag]. 4th General meeting of the EU-6th framevork ip, EUROXY; Bratislava, Slovakia, 8th - 10nd Feb 2006.
  32. Pettersen, Erik O. An integrated project growing out of EUROXY. [Foredrag]. 1st Mid-term meeting of the EU-6th framevork ip, EUROXY, Copenhagen 23rd - 25th Aug 2006.
  33. Pettersen, Erik O. 7th framework program, [Foredrag]. 2nd Mid-term meeting of the EU-6th framevork ip, EUROXY Copenhagen 18th Oct 2006.
  34. Pettersen, Erik O. Consortium answering the FP7 call: Health: Translating the hypoxic tumour microenvironment. Meeting for onsortium establishment for FP7 held in Copenhagen, Denmark; 9th - 10th Feb 2007.
  35. Pettersen, Erik O. Definitions of hypoxia in normal and pathological situations. Euroxy PhD-Course entiteled: Tumour Hypoxia: From Biology to Therapy; held in Maastricht, the Netherlands 26th -28th Feb 2007.
  36. Edin, Nina Frederike J; Sandvik, Joe Alexander; Olsen, Dag Rune; Pettersen, Erik O. Low dose hyper-radiosensitivity in T-47D cells. [Foredrag] Euroxy General Meeting; Vilnius, Lithuania 25th -27th April 2007.
  37. Pettersen, Erik O. Fulfilling Promises. 6th General meeting of EUROXY;in Smolenice, Slovakia 23rd -.25th April 2008.
  1.